A $2.5 billion fundraising campaign launched by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the development of new treatments and ultimately find a cure for Parkinson’s disease has reached the halfway mark, and the nonprofit is plugging for new donations. The multiyear campaign —…
News
A short, personalized intervention teaching people with Parkinson’s disease ways to manage anxiety that can trigger or worsen freezing of gait (FOG) — a common symptom in which individuals can not move their feet forward — did not significantly cut the number of such episodes when compared with no…
In a deal that could be worth more than $300 million, a Korean biotech has acquired exclusive global rights to develop and commercialize 1ST Biotherapeutics‘ 1ST-104, an oral treatment candidate targeting the causes of Parkinson’s disease. SK Biopharmaceuticals will bring its “clinical development and commercialization expertise” to the…
Demographics, social experiences, mental health, and sexual well-being are among factors playing significant roles in shaping health-related quality of life for people with Parkinson’s disease, a study from Ethiopia showed. “The age of participants, sex, coping [strategies], social support, [Parkinson’s]-related stigma, depression, sexual dysfunction and health satisfaction were independent…
A Parkinson’s disease therapy delivered through a wearable device eased motor function in some patients with advanced Parkinson’s, according to preliminary observations from an ongoing Phase 1b trial. An independent safety monitoring committee recommended that the trial of SER-252, Serina Therapeutics’ long-acting form of apomorphine, advance to a…
A new clinical trial led by scientists at the Yale School of Medicine is testing whether targeting inflammation in people at high risk of Parkinson’s disease can prevent or slow disease development. In the PRISMS study (NCT06996652), which recently enrolled its first participant, researchers are testing adalimumab, an…
Incorporating a theory focused on maximizing patients’ motivation may enhance the effectiveness of rehabilitation aimed at improving lung function in people with Parkinson’s disease, according to a new study. “This study provides initial evidence that incorporating strategies [to maximize motivation] into respiratory training can enhance [lung function outcomes] in…
Surgeons and neurologists treating Parkinson’s disease now have a clearer, more personalized window into the human brain, thanks to a newly cleared software tool that maps surgical implants and brain pathways. The U.S. Food and Drug Administration (FDA) has granted clearance to Omniscient Neurotechnology for Quicktome Deep Brain…
Researchers identified candidate biomarkers in spinal fluid and blood that showed different patterns among healthy controls, people in a prodromal group at risk of Parkinson’s, and those diagnosed with Parkinson’s disease, suggesting they may help track the disease across stages. The analysis included more than 1,100 participants. “Our data-driven approach…
A new first-in-class treatment for Parkinson’s disease, designed to get past the brain’s protective barrier, was shown to be safe and well-tolerated in an early clinical trial, and to have “robust [central nervous system] exposure.” That’s according to new data from the Phase 1 trial, which involved both patients…
Recent Posts
- MJFF plugging Parkinson’s campaign halfway toward $2.5B funding goal
- My uncle went in as a Parkinson’s patient, but ‘Mr. Dynasty’ came, too
- Anxiety coaching sessions fail to stop freezing of gait in Parkinson’s
- Developer acquires global rights to Parkinson’s drug in deal worth $300M
- Mental health, social support help shape Parkinson’s life quality